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ARTICLE
EGFR-HIF1α signaling positively regulates the
differentiation of IL-9 producing T helper cells
Suyasha Roy 1, Zaigham Abbas Rizvi1, Alexander J. Clarke 2, Felicity Macdonald3, Abhaydeep Pandey4,
Dietmar Martin Werner Zaiss3, Anna Kathrina Simon2 & Amit Awasthi 1✉
Interleukin 9 (IL-9)-producing helper T (Th9) cells are essential for inducing anti-tumor
immunity and inflammation in allergic and autoimmune diseases. Although transcription
factors that are essential for Th9 cell differentiation have been identified, other signaling
pathways that are required for their generation and functions are yet to be explored. Here, we
identify that Epidermal Growth Factor Receptor (EGFR) is essential for IL-9 induction in
helper T (Th) cells. Moreover, amphiregulin (Areg), an EGFR ligand, is critical for the
amplification of Th9 cells induced by TGF-β1 and IL-4. Furthermore, our data show that Areg-
EGFR signaling induces HIF1α, which binds and transactivates IL-9 and NOS2 promoters in
Th9 cells. Loss of EGFR or HIF1α abrogates Th9 cell differentiation and suppresses their anti-
tumor functions. Moreover, in line with its reliance on HIF1α expression, metabolomics
profiling of Th9 cells revealed that Succinate, a TCA cycle metabolite, promotes Th9 cell
differentiation and Th9 cell-mediated tumor regression.
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IL-9, a pleiotropic cytokine of the common γ-chain family, wasinitially identified as a Th2 cytokine until it was defined in2008 that IL-9 is exclusively produced by a distinct subset of
helper T (Th) cells named as “Th9”. The differentiation of Th9
cells is induced primarily by transforming growth factor β1 (TGF-
β1) and IL-41,2. In fact, TGF-β1 can reprogram Th2 cells into Th9
cells3–6 as IL-4 signaling triggers Th9 cell differentiation by
inhibiting TGF-β-mediated expression of Foxp31. In addition to
TGF-β1 and IL-4, cytokines such as IL-1α, IL-1β, IL-25, IL-33,
and thymic stromal lymphopoietin (TSLP) have been shown to
enhance IL-9 in Th9 cells7–11. Other CD4+ T cell subsets such as
Th2, Th17, and iTregs are also known to produce IL-9, however,
in lesser amounts than produced by Th9 cells12–16. Although
cytokines and transcription factors, which initiate the process of
differentiation of Th9 cells are known, the role of metabolic
reprogramming in the generation and functions of Th9 cells is
still not completely understood. Transcription factors that are
downstream to TGF-β1, IL-4, and IL-2 signaling are essential for
Th9 cell differentiation, as the deficiency of either of TGF-β
receptor (TGF-βR), IL-4R or IL-2R impairs Th9 cell
differentiation1–3,17. Transcription factors such as PU.1 (Spi1),
IRF4, BATF, GATA3, IRF1, and HIF1α, are found to play an
essential role in the differentiation and functions of Th9
cells18–23.
Th9 cells are found to exacerbate allergic airway inflammation
in asthma, colitis and eliminate helminth infections24–26.
Importantly, Th9 cells possess potent anti-tumor functions par-
ticularly against melanoma and lung adenocarcinoma27,28. Con-
sistently, IL-9R−/−mice or antibody mediated neutralization of
IL-9 showed enhanced tumor progression while adoptive transfer
of Th9 cells ameliorated tumor development in B16F10 mela-
noma and LLC-1 (Lewis Lung Carcinoma)29. Given the physio-
logical importance of IL-9, particularly in anti-tumor immunity, a
detailed understanding of molecular regulation of IL-9 induction
in Th cells is needed.
Epidermal growth factor receptor (EGFR) is a member of the
ErbB family and has been shown to express on epithelial and
immune cells30. EGFR is activated upon the binding of its cognate
ligands leading to the phosphorylation of its tyrosine kinase
domain. Upon phosphorylation, downstream signaling pathways
such as PI3K/AKT and RAS/MAPK are activated leading to cell
proliferation, differentiation, and survival30. Among other EGFR
ligands, Areg is found to be produced by Th2 cells and is
important for helminth expulsion31. In addition, EGFR is
expressed on Foxp3+ Tregs, and Areg-EGFR signaling is essential
for the suppressive function of Tregs32. EGFR programs Th2 cells
to function in a TCR independent fashion33. However, the role of
Areg-EGFR axis in Th9 cells remains obscure.
EGFR signaling leads to HIF1α activation as shown in pan-
creatic cancer where EGFR maintains glucose metabolism
through the activation of ERK1/2 pathway34. HIF1α plays an
essential role in the differentiation and functions of Th cells35.
HIF1α acts as one of the key metabolic checkpoints in differ-
entiation and functions of Th9, Th17, and Tregs23,36–38. HIF1α
regulates the expression of glycolytic genes and metabolic
reprogramming of T cells from oxidative phosphorylation
(OxPhos) to aerobic glycolysis39. We and others have shown that
HIF1α increases the glycolytic activity in both mouse and human
Th9 cells23,38. However, the regulation of IL-9 induction and
metabolic pathways other than glycolysis, by HIF1α in Th cells
has not been deciphered yet. Moreover, the crosstalk between
EGFR and HIF1α has not been studied in context of IL-9
induction in Th9 cells.
Here, we show a positive regulation of IL-9 induction in Th
cells by the EGFR-HIF1α signaling axis. We delineate a com-
prehensive network of IL-9 regulation in Th cells by the
interactions among different micro-environmental cues and
metabolites with the EGFR-HIF1α signaling cascade and its
potential implications in anti-tumor immunity.
Results
EGFR signaling is essential for Th9 cell differentiation. We and
others have previously identified that TGF-β1 together with IL-4
differentiate naive CD4+ T cells into IL-9-producing Th9 cells1,2.
Since Th9 cells are critically involved in mounting a robust anti-
tumor immune response27,28, we were keen to identify molecular
pathways that lead to the induction of Th9 cells. To do this, naïve
CD4+ T cells from wild-type (WT) mice were sorted as shown
(Supplementary Fig. 1a), and differentiated into Th9 cells for
performing global gene profiling followed by pathways analysis.
Our RNA-Seq data analysis revealed different signaling pathways
which were upregulated and downregulated in Th9 as compared
to Th0 (naïve CD4+ T cells cultured without any cytokines).
Among pathways that are upregulated in Th9 cells, the EGFR
pathway was significantly enriched in Th9 as compared to Th0
cells (Fig. 1a), indicating the involvement of EGFR signaling in
Th9 cell differentiation. In agreement with our RNA-Seq data,
qPCR data also suggests that Egfr is differentially expressed in
Th9 as compared to Th0 cells (Fig. 1b). To substantiate our claim,
we used Egfrflox/floxXCd4-cre mice in which Egfr gene was con-
ditionally deleted in CD4+ T cells. NanoString analysis revealed
that, as compared to WT mice, Th9 cells from Egfrflox/floxXCd4-
cre mice showed downregulation of key transcription factors,
cytokines and chemokines that are known to be associated with
Th9 cells while an upregulation of inhibitory receptors, suggesting
that EGFR is essential for the developmental programming of
Th9 cells (Fig. 1c). Consistently, there was a reduction in Il9
expression and IL-9 production in Th9 cells from Egfrflox/
floxXCd4-cre mice, as compared to WT Th9 cells (Fig. 1d).
Factors such as IL-33, TSLP and NO have been shown to
enhance the generation of Th9 cells induced by TGF-β1 and IL-
411,40,41. However, whether these Th9-enhancing factors influence
EGFR expression in Th9 cells is not known yet. We found that in
the presence of IL-33 and TSLP, IL-9 and EGFR induction was
amplified in Th9 cells (Fig. 1e, f). Further, we used the Nos2−/−mice
to test the effect of NO on Egfr expression, and found that Nos2−/−
Th9 cells showed reduction in IL-9 and EGFR induction as
compared to WT Th9 cells (Fig. 1g), suggesting an association of
EGFR with IL-9 in Th9 cells. However, IL-33 was unable to
completely restore IL-9 induction in Th9 cells in the absence of
EGFR from Egfrflox/floxXCd4-cre mice as compared to WT Th9 cells
(Fig. 1h). It could be possible that IL-33 receptor (IL-33R), in turn,
is regulated by EGFR in Th9 cells. To rule this out, we tested the
expression of IL-33R in WT and EGFR-deficient Th9 cells, and did
not observe any change in the expression of Il33r in EGFR-deficient
Th9 cells as compared to WT Th9 cells (Fig. 1i). These data
indicates that IL-33-induced enhancement of IL-9 in Th9 cells is
mediated through EGFR signaling.
Inhibition of EGFR signaling abrogates anti-tumor functions
of Th9 cells. Anti-tumor functions of Th9 cells have been clearly
demonstrated in melanoma28. Our data indicates that EGFR
signaling is essential for the differentiation of Th9 cells. To
functionally validate the role of EGFR signaling in Th9 cells, we
inhibited EGFR functions in Th9 cells using gefitinib, which
inhibits the tyrosine kinase activity of EGFR by binding to its
ATP-binding domain. Naïve CD4+ T cells isolated from WT
mice were differentiated into Th9 cells in the absence or presence
of gefitinib to further test the effect of EGFR inhibition on Th9
cells. Blocking EGFR signaling by gefitinib significantly inhibited
the Il9 expression and IL-9 production in Th9 cells (Fig. 2a, b). To
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test the in vivo effect of EGFR inhibition, naïve CD4+ T cells
from OT-II TCR transgenic mice were in vitro polarized into Th9
cells in the presence or absence of gefitinib. These cells were then
adoptively transferred into a B16-OVA tumor-bearing WT mice
and the tumor progression was monitored. Th9 cells significantly
regressed tumor growth while the anti-tumor functions of Th9
cells was abrogated in the presence of gefitinib (Fig. 2c). Further,
we found a decrease in the frequency of IFN-γ producing CD8+
and CD4+ T lymphocytes in the spleen as well as in the tumor
draining lymph nodes (dLN) in the group of mice transferred
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with gefitinib-treated OT-II Th9 cells as compared to OT-II-Th9
cells (Fig. 2d, e and Supplementary Fig. 2a–f). Frequencies of both
CD8+ IFN-γ+ and CD4+ IFN-γ+ tumor-infiltrating lymphocytes
(TILs) were also reduced within the gefitinib-treated group
(Fig. 2f and Supplementary Fig. 2g, h). These data suggests that
EGFR signaling is required for the anti-tumor functions of Th9
cells. Next, sorted human naïve CD4+ T cells (Supplementary
Fig. 1b) were differentiated into Th9 cells with or without gefi-
tinib. Likewise, blocking EGFR signaling by gefitinib suppressed
EGFR and IL-9 induction in human Th9 cells also (Fig. 2g, h).
Taken together, these data emphasizes that EGFR signaling is
essential for Th9 cell differentiation in both mouse and humans.
Since IL-9 is known to be also produced by Th2, Th17, and
Tregs although in lesser amounts15,16,18, so we next tested the
effect of EGFR inhibition on IL-9 induction in Th2, Th17, and
iTregs. We found that blocking EGFR signaling using gefitinib
significantly suppressed the IL-9 induction in Th2, Th17, and
iTregs (Supplementary Fig. 3a). In addition to IL-9, in vitro
differentiated Th9 cells also produce IL-101 while Th9 cells
eliminate tumor in vivo by triggering IFN-γ production by CD8+
T cells22. To understand whether EGFR-deficient Th9 cells tend
to produce IL-10 and/or IFN-γ and have the potential to adopt
different phenotypes, WT and EGFR-deficient CD4+ T cells were
differentiated into Th9 cells and the levels of IL-10 and IFN-γ
were determined. There were no significant changes observed in
the induction of both IL-10 and IFN-γ in EGFR-deficient Th9
cells as compared to WT Th9 cells (Supplementary Fig. 3b, c).
These results apparently, indicates that the abrogation of EGFR
signaling repressed IL-9 induction without influencing the
expression of other cytokines in Th9 cells.
Areg is required for EGFR-mediated IL-9 induction in Th cells.
Since EGFR activation requires the binding of its ligands, there-
fore we tested the expression of different EGFR ligands in Th9
cells, and found that Areg was upregulated both at mRNA and
protein level in Th9 cells as compared to Th0 cells (Fig. 3a). Other
EGFR ligands such as Tgfα, Egf, and Begf were not found to be
expressed in Th9 cells as compared to Th0, suggesting a potential
role of Areg-EGFR axis in the differentiation and functions of
Th9 cells (Supplementary Fig. 4a). Interestingly, Th2, Th17, and
iTregs expressed Areg and Egfr, in addition to Il9, at lower levels
as compared to Th9 cells, indicating a positive correlation
between Areg and IL-9 induction in Th cells (Supplementary
Fig. 4b). To further validate the role of Areg in Th9 cell differ-
entiation, we polarized Th9 cells in vitro with or without exo-
genous Areg. In the presence of exogenous Areg, the expression
of Il9 and IL-9 production increased significantly in Th9 cells
(Fig. 3b, c). In addition, the expression of Th9-associated genes,
Spi1 and Irf4, was increased in Th9 cells cultured with exogenous
Areg as compared to Th9 cells cultured without exogenous Areg
(Fig. 3d). Moreover, exogenous Areg also enhanced Egfr expres-
sion in Th9 cells as compared to Th9 cells cultured without
exogenous Areg (Fig. 3d). Consistently, Areg also boosted IL-9
and EGFR induction in Th2, Th17, and iTregs (Supplementary
Fig. 4c). Furthermore, Th9-enhancing factors such as IL-3310,40
and TSLP11, led to an enhanced Areg expression in Th9 cells
(Fig. 3e). In line with these observations, Areg neutralization with
anti-Areg antibody significantly abrogated Il9 and Egfr expression
and IL-9 production in Th9 cells (Fig. 3f). Similar to the findings
in mouse Th9 cells, supplementation of exogenous Areg also
increased EGFR and IL-9 induction in human Th9 cells (Fig. 3g).
To further substantiate our claim on the role of Areg in Th9
cell differentiation, we isolated naïve CD4+ T cells from WT
and Areg−/− mice and differentiated them into Th9 cells.
Transcriptomics profiling identified differentially expressed
genes in Areg−/− Th9 cells as compared to WT Th9 cells
(Fig. 3h). Il9 was identified among the top downregulated
genes in Areg−/− Th9 cells as compared to WT Th9 cells
(Fig. 3i). We validated our RNA-Seq data by qPCR, and found
that the expression of Il9 and Th9 cell-associated transcription
factors, Spi1 and Batf, were decreased in Areg−/− Th9 cells as
compared to WT Th9 cells (Fig. 3j). In addition, as compared
to WT Th9 cells, Areg−/− Th9 cells showed a reduced
expression of Egfr without affecting the expression of Il33r
(Fig. 3j, k), suggesting that Areg is essential for EGFR and IL-9
induction in Th9 cells. There was also diminished IL-9
production in Areg−/− Th9 cells as compared to WT Th9
cells (Fig. 3l). Apparently, there was diminished IL-9
induction and Egfr expression in Th2, Th17, and iTregs upon
Areg deletion (Supplementary Fig. 4d). While exogenous Areg
failed to enhance Il9 expression in Th0 cells (Supplementary
Fig. 4e), exogenous Areg together with TGF-β1 plus IL-4
resulted in a higher Il9 expression as compared to TGF-β1 or
IL-4 alone (Supplementary Fig. 4f). Strikingly, in Egfrflox/
floxXCd4-cre mice, Areg could not completely restore IL-9
induction in Th9 cells as compared to WT mice (Fig. 3m),
indicating the fact that Areg mediates its effect on the
differentiation of Th9 cells via EGFR. We further tested
whether Areg-deficient Th9 cells produce IL-10 and IFN-γ, as
these cytokines were found to be produced by Th9 cells
in vitro and in vivo respectively. Our data indicates that there
were no differential induction of IL-10 and IFN-γ in Areg-
deficient Th9 cells, as compared to WT Th9 cells (Supple-
mentary Fig. 4g, h). Taken together, these data demonstrated
Fig. 1 EGFR pathway is essential for Th9 cell differentiation. a Naïve CD4+ T cells from WT mice were in vitro differentiated into Th0 and Th9 followed
by RNA-Seq and ingenuity pathway analysis. b qPCR analysis of Egfr expression. Data are representative of mean ± SEM from three independent
experiments. c, d Naïve CD4+ T cells fromWT and Egfrflox/floxXCd4-cremice were in vitro differentiated under Th0 and Th9 polarizing conditions for 3 days
followed by c. NanoString analysis. Fold change in relative expression relative to control was determined by log2 (Th9 Egfrflox/floxXCd4-cre/Th9 WT).
d qPCR analysis of Il9 expression and ELISA for IL-9 production. Data are representative of mean ± SEM from three independent experiments. e, f Naïve
CD4+ T cells from WT mice were in vitro differentiated under Th9 polarizing conditions with or without 10 ng/ml IL-33 or 10 ng/ml TSLP for 3 days
respectively; e qPCR analysis of Il9, Egfr expression and f ELISA for IL-9. Data are representative of mean ± SEM from three independent experiments.
g Naïve CD4+ T cells from WT and Nos2−/− mice were differentiated under Th9 polarizing conditions followed by qPCR analysis of Il9 and Egfr expression
and ELISA for IL-9. Data are representative of mean ± SEM from three independent experiments. h Naïve CD4+ T cells from WT and Egfrflox/floxXCd4-cre
mice were differentiated under Th9 polarizing conditions with or without 10 ng/ml IL-33 for 3 days; qPCR analysis of Il9 expression and ELISA for IL-9. Data
are representative of mean ± SEM from three independent experiments. i Naïve CD4+ T cells from WT and Egfrflox/floxXCd4-cre mice were differentiated to
Th9 followed by qPCR analysis of Il33r expression. Data are representative of mean ± SEM from three independent experiments. b **P= 0.007, using two-
tailed unpaired Student’s t test. d *P= 0.033, ****P < 0.00001, ***P= 0.0007, using two-way ANOVA followed by Tukey’s multiple comparison test.
e, f *P= 0.04, **P= 0.002, ****P < 0.0001, using one-way ANOVA followed by Tukey’s multiple comparison test. g **P= 0.003, ***P= 0.0009, *P=
0.01, using two-tailed unpaired Student’s t test. h *P= 0.05, ***P= 0.0009, **P= 0.001, ****P= 0.0001, using two-way ANOVA followed by Tukey’s
multiple comparison test. i P = ns (not significant), using two-tailed unpaired Student’s t test.
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that Areg-mediated EGFR activation amplifies IL-9 induction
in IL-9 producing Th cells.
HIF1α is critical for IL-9 induction in Th cells. Transcription
factor HIF1, composed of HIF1α and HIF1β subunits, is involved
predominantly in controlling the differentiation and functions of
Th cells35. We have previously reported the impact of HIF1α on
IL-9 induction in human Th9 cells38, and it is known that HIF1α
promotes mouse Th9 cell differentiation23. Our RNA-Seq analysis
identified an upregulation of Il9 and Hif1α genes expression in
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Th9 cells (Fig. 4a, b). Among other transcription factors, HIF1α
was found to be a major transcription factor that is crucial for
metabolic regulation of T cell differentiation. Considering the role
of HIF1α in influencing the metabolomic regulation in T cells
differentiation, we picked HIF1α to identify its role at molecular
level in the induction of IL-9 in Th cells. Moreover, it has been
demonstrated that Areg-EGFR signaling merges to HIF1α, and
consistently our NanoString data (Fig. 1c, left most panel) indi-
cated that the expression of HIF1α was substantially down-
regulated in EGFR-deficient Th9 cells as compared to WT Th9
cells, which led us to focus on HIF1α in order to identify the
significance of Areg-EGFR-HIF1α axis in the differentiation and
function of Th9 cells.
To elucidate the downstream signaling cascade of EGFR
pathway, we sought to investigate the role of EGFR-HIF1α axis in
IL-9 induction and whether Areg-EGFR axis converge to HIF1α
during Th9 cell differentiation. We found that Th9 cells from
Egfrflox/floxXCd4-cre mice failed to express Hif1α as compared to
WT Th9 cells (Fig. 4c). Moreover, inhibition of EGFR signaling
by gefitinib resulted in the abrogation of Hif1α expression while
in the presence of exogenous Areg, Hif1α expression was
remarkably increased (Fig. 4d and Supplementary Fig. 5a),
suggesting that Areg-EGFR pathway induces HIF1α in Th9 cells.
To demonstrate the functional association of HIF1α with IL-9,
we identified four putative HIF1α-binding sites in the proximal
promoter of IL-9. We performed the chromatin immunopreci-
pitation (ChIP) assay to confirm the physical binding of HIF1α to
IL-9 promoter, and found that HIF1α binds to all the four
putative HIF1α-binding sites on IL-9 promoter in Th9 cells
(Fig. 4e). To further establish the functionality of HIF1α binding
to IL-9 promoter, we performed luciferase reporter assay to
measure IL-9-promoter driven-luciferase activity. Our data
confirmed that HIF1α transactivates IL-9 promoter activity
resulting in increased Il9 transcription (Fig. 4f). In addition to
HIF1α binding to IL-9 promoter in Th9 cells, our ChIP data also
confirmed that HIF1α binds to IL-9 promoter in Th2, Th17 cells
as well as iTregs, since these cells tend to produce lower amounts
of IL-9, as compared to Th9 cells (Supplementary Fig. 5b–d).
The physiological role of HIF1α in IL-9 induction was
validated by knocking down Hif1α gene in CD4+ T cells using
Hif1αkd mice in which shRNA silences Hif1α expression upon
doxycycline (Dox) induction. Naïve CD4+ T cells, isolated from
WT and Hif1αkd mice, were in vitro differentiated into Th9, Th2,
Th17, and iTregs with daily treatment of 1.0 μg/ml Dox for
3 days. qPCR and ELISA results showed that Il9 expression was
decreased and IL-9 secretion was also dampened in Th9 cells
differentiated from Hif1αkd mice as compared to WT mice
(Fig. 4g). Consistently, it was observed that the other IL-9-
producing T cells such as Th2, Th17 cells and iTregs from
Hif1αkd mice as compared to WT mice, have shown reduced IL-9
induction at both mRNA and protein levels (Fig. 4h), suggesting
that HIF1α is essentially required for IL-9 induction in Th cells.
As indicated earlier, we did not find any substantial difference in
the induction of cytokines, IL-10 and IFN-γ when Hif1α was
knocked down in Th9 cells (Supplementary Fig. 5e, f). To test the
physiological relevance of HIF1α expression in Th9 cells, we
performed Th9 cells adoptive transfer experiments in B16-OVA
melanoma model, and observed that the anti-tumor activity of
Th9 cells was abrogated in the presence of acriflavine (ACF), a
HIF1α inhibitor42 (Fig. 4i, j). Taken together, these results clearly
demonstrates the role of EGFR-HIF1α axis in the induction and
functions of Th9 cells.
PHD2 and Hypoxia-mediated HIF1α stabilization and IL-9
induction in Th cells. Since we showed that EGFR-HIF1α axis is
critical for IL-9 induction in Th cells, we next sought to investigate
the role of regulators of HIF1α stability and its subsequent effect on
IL-9 induction in Th cells. It has been reported that HIF1 and HIF2
is stable in the absence of prolyl hydroxylases 2 (PHD2)43–46. To
test the role of PHD2 in IL-9 induction, we used Dox-inducible
Phd2kdmice47 in which Phd2 gene encoding for prolyl hydroxylases
2 (PHD2) was knocked down upon Dox treatment. Naïve CD4+
T cells isolated from WT and Phd2kd mice were differentiated
under Th9 polarizing conditions with daily treatment of 1.0 μg/ml
Dox for 3 days. qPCR analysis suggests an upregulation of Hif1α in
Th9 cells from Phd2kdmice as compared to WT mice (Fig. 5a). This
is in accordance with the previous findings suggesting that Hif1α
expression is higher and more stable in the absence of PHD2 43.
PHD2 regulates both HIF1 and HIF2 activation and consistently,
Il9 expression was found to be higher in Phd2kd mice as compared
to WT mice (Fig. 5a, right most panel). This could be due to the
higher HIF stability triggering an enhanced Il9 expression in Th9
cells in the absence of PHD2. Further, we checked Th9-associated
genes through qPCR and found that Spi1, Irf1, and Batf were
upregulated in Th9 cells from Phd2kd mice as compared to WT
mice (Fig. 5a). IL-9 production was also increased in Th9 cells from
Phd2kd mice as compared to WT mice (Fig. 5b). In addition, we
found that PHD2 knockdown, using the Phd2kd mice, significantly
enhanced IL-9 induction at both mRNA and protein levels in Th2,
Th17 and iTregs as well (Supplementary Fig. 6a), illustrating that
knocking down Phd2 gene promotes IL-9 induction in all Th cells.
In addition to the EGFR pathway, RNA-Seq re-analysis of
mouse Th9 cells identified the “enrichment of glycolysis” and
“response to hypoxia” pathways in Th9 cells (Fig. 5c). We have
previously shown that HIF1α is stabilized and constitutively
expressed in hypoxic condition which triggers human Th9 cell
differentiation38. Corroborating our published human data38,
mouse Th9 cells differentiated in hypoxic conditions showed an
increase in the expression of Il9, Hif1α, and signature genes in
Th9 cells (Fig. 5d). HIF1α protein stability was further
enhanced in hypoxia in comparison to normoxia in Th9 cells
(Fig. 5e). IL-9 production by Th9 cells was also increased in
Fig. 2 EGFR inhibition abrogates the anti-tumor functions of Th9 cells. a, b Naïve CD4+ T cells from WT mice were in vitro differentiated under Th9
conditions with or without 1.0 μM gefitinib for 3 days followed by a. qPCR analysis of Il9 expression. b ELISA for IL-9 and flow cytometry analysis of
intracellular staining for IL-9 and IL-17. Data are representative of mean ± SEM from three independent experiments. c–f Naïve CD4+ T cells from OT-II
TCR transgenic mice were in vitro differentiated into Th9 with or without 1.0 μM gefitinib for 3 days. Cells were then adoptively transferred into B16-OVA
tumor-bearing WT mice, randomized into three groups (n= 5 mice per group). c Mean tumor volume was measured over time shown as tumor growth
curve. d, e Spleen and tumor draining lymph nodes (dLN) were harvested and single cell suspensions were made followed by FACS analysis of intracellular
staining for CD4+IFNγ+ and CD8+IFNγ+. f TILs were isolated from the tumor followed by FACS analysis of intracellular staining for CD8+IFNγ+and
CD4+IFNγ+ cell populations. Data are representative of mean ± SEM from three independent experiments. g, h Sorted naïve human CD4+ T cells were
differentiated into Th9 cells with or without 1.0 μM gefitinib. g mRNA expression of Egfr and Il9 was determined by qPCR. Data are representative of mean
± SEM from three healthy individuals. h Intracellular staining for IL-9. a, b ***P= 0.0003, *P= 0.017, using two-tailed unpaired Student’s t test. c ****P <
0.0001, using two-way ANOVA followed by Tukey’s multiple comparison test. d–f ****P < 0.0001, **P= 0.001, ***P= 0.0001, *P= 0.02, using one-way
ANOVA followed by Tukey’s multiple comparison test. g *P= 0.014, using two-tailed unpaired Student’s t test.
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hypoxia (Fig. 5f). In addition, IL-9 induction was also enhanced
in Th2, Th17, and iTregs differentiated under hypoxic
conditions (Supplementary fig. 6b). All together, these data
exemplifies that PHD2 and hypoxia stabilizes HIF1α boosting
IL-9 induction in Th cells.
NO and HIF1α synergistically triggers IL-9 induction in Th9
cells. It is known that NO enhances Th9 cell differentiation41 and
we found an association between NO and HIF1α in human Th9
cells38. Our data suggests that NO is required for EGFR expres-
sion in Th9 cells (Fig. 1g). However, the link between NO and
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HIF1α in context of IL-9 induction in mouse Th cells is not yet
known. To test this hypothesis, we examined the effect of NO in
Th9 cells using Nos2−/− mice. We found that the expression of
Th9-associated genes, Spi1, Irf4, Gata3, and Batf were down-
regulated in Nos2−/− Th9 cells as compared to WT Th9 cells
(Fig. 6a). Consistently, IL-9 production was also reduced in
Nos2−/− Th9 cells (Fig. 6b). However, there was no detectable
difference in the induction of IL-10 and IFN-γ in Nos2−/− Th9
cells as compared to WT Th9 cells (Supplementary Fig. 7a, b). In
addition, IL-9 induction was also diminished in Nos2−/− Th2,
Th17, and iTregs, suggesting that NO is essential for IL-9
induction in all IL-9 producing Th cell subsets (Supplementary
Fig. 7c). It has been shown that NO promotes HIF1α
stabilization48 and we also found that the expression of Hif1α was
inhibited in Nos2−/− Th9 cells (Fig. 6c). Interestingly, ChIP and
luciferase assays showed that HIF1α binds and transactivates
Nos2 promoter (Fig. 6d, e). This was further corroborated with
the finding that Hif1αkd Th9 cells express reduced Nos2 expres-
sion in Th9 cells (Fig. 6f). Similarly, Nos2 expression was higher
in Th9 cells cultured in hypoxia as compared to normoxia
(Fig. 6g). Consistently, Nos2 expression was also elevated in Th9
cells from Phd2kd mice as compared to WT mice (Fig. 6h), sug-
gesting that increased HIF1α activity results in higher Nos2
expression in Th9 cells. These data interprets that NO and HIF1α
creates a feed-forward loop to promote Th9 cell differentiation
synergistically.
αKG and succinate reciprocally regulates HIF1α and IL-9
induction in Th9 cells. It is well known that metabolic regulation
plays a key role in Th cell differentiation49, and our data indicates
a critical role of HIF1α in Th9 cell differentiation. Since HIF1α is
one of the known transcription factor that regulate metabolic
pathways in T cells, we performed metabolomics profiling in Th9
cells from WT and Hif1αkd mice to identify the key metabolites
and metabolic pathways regulated by HIF1α essential for the
generation of Th9 cells. To do this, we quantified metabolites of
different metabolic pathways in cell extracts as well as cell-free
culture supernatants (footprinting). Metabolomics data demon-
strated a differential expression of metabolites in WT and Hif1αkd
Th9 cells (Fig. 7a). There was a decreased production of meta-
bolites of glycolysis, pentose phosphate pathway (PPP), fatty acid
pathway and energy metabolites in Hif1αkd Th9 cells as compared
to WT Th9 cells (Fig. 7a–c and Supplementary Fig. 8a–c). Hif1αkd
decreased ATP and lactate (Lac) production in Th9 cells (Fig. 7c,
d). We further identified a striking decrease in α-ketoglutarate
(αKG), a TCA cycle metabolite in Hif1αkd Th9 cells (Fig. 7e)
which led us to further investigate and validate its role in Th9 cell
differentiation.
Metabolomics analysis illustrated a decrease in αKG produc-
tion in Hif1αkd Th9 cells, suggesting a possible link between the
production of αKG and HIF1α in Th9 cells. It has been
demonstrated that αKG increases PHD2 activity leading to
inactivation of HIF1α in macrophages50. This led us to investigate
the role of αKG in HIF1α-dependent Th9 cell differentiation.
NanoString analysis of Th9 cells cultured in the presence of αKG
showed the downregulation of key transcription factors and
cytokines signature of Th9 cells (Fig. 7f). Consistently, we found
that αKG inhibited the induction of both HIF1α and IL-9 in Th9
cells while led to an increase in Egln1 expression (gene encoding
for PHD2) which corresponds to an enhanced PHD2 activity
(Fig. 7g–i).
αKG is subsequently converted to succinate through GABA
transaminase (GABA-T)50. Succinate increases Hif1α expression
and decreases PHD2 activity50,51. Vigabatrin, an irreversible
inhibitor of GABA transaminase, leads to decreased succinate
formation and increased accumulation of αKG eventually
depleting HIF1α50. In line with these findings, we found that
vigabatrin significantly decreased HIF1α and IL-9 induction
possibly due to the accumulation of αKG in Th9 cells
(Supplementary Fig. 9a, b).
Succinate is derived from glutamine either through anaplerosis
via αKG or through “GABA shunt pathway”. Succinate is
transported to the cytosol from the mitochondria where it creates
‘pseudohypoxia’ by impairing PHD2 activity leading to HIF1α
stabilization and activation. This effect is blocked by αKG, the
substrate for PHD2 that generates succinate as a by-product in
HIF1α hydroxylation52,53. We have shown that αKG depletes
HIF1α and suppresses IL-9 in Th9 cells. Next, we tested the effect
of succinate on HIF1α and IL-9 induction, and found that
succinate increases the expression of Il9, Spi1, Irf4, Irf1, Gata3,
and IL-9 production in Th9 cells (Fig. 7j, k). We found that
succinate impaired PHD2 activity by inhibiting Egln1 expression,
which resulted in increased Hif1α expression in Th9 cells,
implying that succinate stabilizes HIF1α and enhances IL-9
Fig. 3 Areg promotes EGFR-mediated Th9 cell differentiation. a Naïve CD4+ T cells from WT mice were differentiated into Th0 and Th9 followed by
qPCR analysis and ELISA for Areg. Data are representative of mean ± SEM from three independent experiments. b–d Naïve CD4+ T cells from WT mice
were differentiated into Th0 and Th9 with or without 100 ng/ml Areg followed by b qPCR analysis of Il9 expression. c FACS staining for IL-9 and IL-17 and
ELISA for IL-9. d qPCR for Spi1, Irf4, and Egfr expression. Data are representative of mean ± SEM from three independent experiments. e Naïve CD4+ T cells
from WT mice were differentiated under Th9 polarizing conditions with or without 10 ng/ml IL-33 or 10 ng/ml TSLP respectively for 3 days followed by
qPCR analysis of Areg expression. Data are representative of mean ± SEM from three independent experiments. f Naïve CD4+ T cells from WT mice were
differentiated into Th9 in the presence of isotype antibody (Ab) or anti-Areg Ab followed by qPCR analysis of Il9, Egfr expression and ELISA for IL-9. Data
are representative of mean ± SEM from three independent experiments. g Sorted naïve human CD4+ T cells were differentiated into Th9 cells with or
without 100 ng/ml Areg. qPCR analysis of Il9 and Egfr expression and FACS for IL-9. Data are representative of mean ± SEM from three healthy individuals.
h–l Naïve CD4+ T cells from WT and Areg−/− mice were differentiated under Th9 polarizing conditions. h Heat-map of significantly differentially
expressed genes in Th9 cells from WT and Areg−/− mice after RNA-Seq analysis. i Heat-map for RNA-Seq analysis of selected significantly differentially
expressed genes in Th9 cells from WT and Areg−/− mice. j, k qPCR analysis of Il9, Spi1, Batf, Egfr, and Il33r expression. l ELISA for IL-9 and flow cytometry
analysis of intracellular staining for IL-9. Data are representative of mean ± SEM from three independent experiments. m Naïve CD4+ T cells from WT and
Egfrflox/floxXCd4-cre mice were differentiated under Th9 polarizing conditions with or without 100 ng/ml Areg for 3 days; qPCR analysis of Il9 expression
and ELISA for IL-9. Data are representative of mean ± SEM from three independent experiments. a ****P < 0.0001, *P= 0.04, using two-tailed unpaired
Student’s t test. b *P= 0.02, using one-way ANOVA followed by Tukey’s multiple comparison test. c *P= 0.02 using one-way ANOVA followed by
Tukey’s multiple comparison test. d ****P < 0.0001, ***P= 0.0003, using two-tailed unpaired Student’s t test. e *P= 0.01, using one-way ANOVA followed
by Tukey’s multiple comparison test. f *P= 0.01, P= ns (not significant), **P= 0.005, using two-tailed unpaired Student’s t test. g **P= 0.0044, ***P=
0.0006, using two-tailed unpaired Student’s t test. j, k ****P < 0.0001, *P= 0.02, P= ns (not significant), using two-tailed unpaired Student’s t test. l *P=
0.04, using two-tailed unpaired Student’s t test. m *P= 0.01, **P= 0.001, ***P= 0.0006, using two-way ANOVA followed by Tukey’s multiple
comparison test.
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induction in Th9 cells (Fig. 7l). There was no significant influence
of αKG and succinate on the induction of IL-10 and IFN-γ
respectively (Supplementary Fig. 10a–d). Moreover, in compar-
ison to TGF-β1 or IL-4 alone, TGF-β1+ IL-4 together resulted in
a greater increase in Il9 expression in the presence of succinate in
the Th9 cells (Supplementary Fig. 10e). Also, there was no
differential Il9 expression in Th0 cells in the presence or absence
of succinate (Supplementary Fig. 10f). Finally, we examined the
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in vivo role of succinate in the anti-tumor functions of Th9 cells
in B16-OVA melanoma tumor model. We found that the tumor
volume was significantly decreased in mice which received OT-II-
Th9 cells as compared to the B16-OVA control mice (Fig. 7m).
Strikingly, in comparison to OT-II-Th9 cells, succinate-treated
OT-II-Th9 cells led to a greater reduction in the tumor volume
(Fig. 7m), implying that succinate enhances the differentiation
and anti-tumor functions of Th9 cells through increased
stabilization of HIF1α by impairing PHD2 activity.
Based on the experimental data provided in this study, we
propose a model for Th9 cell differentiation. TGF-β1 plus IL-4
initiates Th9 cell differentiation from naïve CD4+ T cells. Areg-
EGFR signaling axis amplifies Th9 cell differentiation through
EGFR-mediated activation of the transcription factor, HIF1α.
HIF1α promotes Th9 cell differentiation: (i) metabolically
through TCA cycle metabolite, Succinate, and (ii) transcription-
ally by transactivating Il9 and Nos2 gene loci, further enhancing
Th9 cell polarization and Th9 cell-mediated anti-tumor effector
functions (Fig. 8).
Discussion
The importance of Th9 cells in health and diseases is discussed
for the reason that IL-9 and IL-9R are crucial for disease
pathogenesis in allergic inflammation. It has been previously
shown that genetic polymorphism in the Il9 gene is linked with
an increased risk of developing cutaneous malignant
melanoma54. Subsequent studies clearly showed that Th9 cells
mount more potent anti-tumor immunity as compared to Th1,
Th2 and Th17 cells22,27,28. However, the generation of Th9 cells
are still not completely understood which led to an impetus for
unraveling the unknown molecular pathways in the development
and functions of Th9 cells. Our RNA-Seq analysis identified a
strong upregulation of EGFR pathway in mouse Th9 cells. Inhi-
bition of EGFR suppressed the IL-9 induction in all Th cells and
our data indicates that EGFR pathway is crucial for the anti-
tumor functions of Th9 cells.
Activation of EGFR signaling is induced by phosphorylation,
which subsequently activates downstream signaling
components30. We found that Th9 cells produce Areg, an EGFR
ligand, which has previously shown to play an important role in
mediating effector and regulatory functions of Th231 and Tregs32
respectively. Th9 shares gene program closer to Th2 and Tregs by
virtue of the common differentiation factors such as TGF-β1 with
Tregs and IL-4 with Th2 respectively. This suggests a possibility
for the involvement of Areg in Th9 cells. Our data has identified
that Areg enhances Th9 cell differentiation. EGFR-mediated IL-9
induction was significantly impaired in Areg−/− mice in which
the expression of Egfr, Il9 and Th9-associated genes were sup-
pressed. It is reported that EGFR activation leads to STAT3
activation, and STAT3 is a negative regulator of Th9 cells. Since
the in vitro culture conditions for Th9 cell differentiation con-
tains IL-4, it is possible that IL-4-induced STAT6 might antag-
onize the functions of STAT3 activated by Areg-EGFR, and as a
result, Areg-EGFR-mediated activation of STAT3 may not be able
to exert its negative effect on Th9 cell differentiation. In addition,
Areg-EGFR signaling leads to the activation of NFκB, which is
found to be essential for the differentiation of Th9 cells, as NFκB
inhibition leads to the suppression of Th9 cells. It is, however, not
clear whether Areg-EGFR-mediated activation of NFκB is
dominant over STAT3 activation, and thus promotes Th9 cell
differentiation.
Since IL-9 is also produced by other Th cells such as Th2,
Th17, and iTregs55, we found that both Areg and EGFR are
required for IL-9 induction in Th2, Th17, and iTregs as well.
Thus, Areg-mediated EGFR signaling is required for IL-9
induction in all IL-9-producing Th cells. Further, we have
shown that Th9-enhancing cytokines like IL-33 and TSLP
enhances IL-9 induction in Th9 cells through increased expres-
sion of Areg and Egfr. This was evident when IL-33 could not
completely rescue IL-9 induction in Th9 cells in the absence of
EGFR. We also showed that NO is critical for Egfr expression and
IL-9 induction in Th9 cells. Therefore, IL-33, TSLP, and NO
serves as Th9-enhancing factors which functions through Areg-
EGFR pathway.
Upon activation, EGFR signals through PI3K/AKT, RAS/MAPK
pathways, which leads to cell proliferation, differentiation, and
survival30. We further wanted to understand the downstream
pathways of EGFR signaling that are important for triggering Th9
cell differentiation. Studies have shown a link between EGFR and
HIF1α in tumor cells34, however, the role of EGFR-HIF1α axis has
not been elucidated in T cells so far. Our NanoString analysis
revealed a strong downregulation of the transcription factor, HIF1α
in Th9 cells from Egfrflox/floxXCd4-cre mice as compared to WT
Th9 cells. This compelled us to focus on HIF1α intriguingly for
elucidating its role in the regulation of IL-9 induction in Th cells.
HIF1α and HIF2α are closely related isoforms of HIF, and both
of these isoforms induce HRE-dependent gene expression56.
Despite having similarities in their functions, knockout mice
studies indicate non-redundant roles of HIF1α and HIF2α, and
Fig. 4 HIF1α is critical for IL-9 induction in Th cells. a, b Heat-map for RNA-Seq analysis of significantly differentially expressed genes in Th9 cells as
compared to Th0 cells. c Naïve CD4+ T cells fromWT and Egfrflox/floxXCd4-cremice were differentiated under Th0 and Th9 polarizing conditions for 3 days
followed by qPCR analysis of Hif1α expression. Data are representative of mean ± SEM from three independent experiments. d Naïve CD4+ T cells from
WT mice were differentiated under Th9 polarizing conditions with or without 1.0 μM gefitinib for 3 days followed by qPCR analysis of Hif1α expression.
Data are representative of mean ± SEM from three independent experiments. e Bioinformatics analysis of HIF1α binding motif in IL-9 promoter. ChIP
analysis of HIF1α binding to IL-9 promoter in Th9 cells represented as enrichment of HIF1α on IL-9 promoter relative to input. Data are representative of
mean ± SEM from three independent experiments. f Luciferase reporter assay for IL-9 promoter activity in the presence of HIF1α plasmid at 0, 100, and
200 ng concentrations. Data are representative of mean ± SEM from three independent experiments. g, h Naïve CD4+ T cells from WT and Hif1αkd mice
were differentiated under Th9, Th2, Th17, iTregs polarizing conditions with daily treatment of 1.0 μg/ml Dox for 3 days followed by qPCR analysis of Il9
expression and ELISA for IL-9 production. Data are representative of mean ± SEM from three independent experiments. i Naïve CD4+ T cells from WT
mice were differentiated into Th9 cells with or without 5.0 μM acriflavine (ACF) followed by qPCR analysis of Il9 expression. j Naïve CD4+ T cells from OT-
II TCR transgenic mice were differentiated into Th9 cells with or without 5.0 μM acriflavine (ACF). At day 4, cells were adoptively transferred into B16-
OVA tumor-bearing WT mice, randomized into three groups. Mean tumor volume was measured over time. Data are representative of mean ± SEM from
three independent experiments, (n= 5 mice per group). c ***P= 0.0004, using two-way ANOVA followed by Tukey’s multiple comparison test. d ***P=
0.0006, using two-tailed unpaired Student’s t test. e *P= 0.04, **P= 0.009, ***P= 0.0003, using two-tailed unpaired Student’s t test. f ***P= 0.0009,
****P < 0.0001, using one-way ANOVA followed by Tukey’s multiple comparison test. g, h *P= 0.02, **P= 0.0027, ***P= 0.0002, ****P < 0.0001, P= ns
(not significant), using two-tailed unpaired Student’s t test. i **P= 0.01, using two-tailed unpaired Student’s t test. j **P= 0.0014, using two-way ANOVA
followed by Tukey’s multiple comparison test.
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inactivation of one or other results in a distinctly different phe-
notype, which could be due to their tissue-specific and temporal
expression57. Nonetheless, both of HIF1α and HIF2α isoforms
could be also expressed in the same cells but may have different
transcriptional targets. HIF1α, but not HIF2α, is the major factor
that controls glycolytic pathway58. We and others have shown
that Th9 cells expressed genes that are essential for glycolytic
pathway23,38. In addition, it has been demonstrated that T cell
activation primarily relies on the glycolytic pathway for fulfilling
an increased energy demand and providing metabolic precursors
Fig. 5 PHD2 and Hypoxia-mediated HIF1α stabilization and IL-9 induction in Th cells. a, b Naïve CD4+ T cells from WT and Phd2kd mice were
differentiated under Th9 polarizing conditions with daily treatment of 1.0 μg/ml Dox for 3 days. a qPCR analysis of Hif1α, Spi1, Irf1, Batf and Il9 expression.
Data are representative of mean ± SEM from three independent experiments. b ELISA and FACS for IL-9 production. Data are representative of mean ± SEM
from three independent experiments. c Pathway analysis depicting the enrichment of pathways associated with HIF1α in WT Th9 cells. d–f Naïve CD4+
T cells from WT mice were differentiated into Th9 under normoxic (21% oxygen) or hypoxic (1.0% oxygen) conditions for 3 days. d qPCR analysis of Il9,
Hif1α, Spi1, Gata3, Irf4, and Irf1 expression. Data are representative of mean ± SEM from three independent experiments. e FACS staining for HIF1α. f IL-9
production by flow cytometry and ELISA. Data are representative of mean ± SEM from three independent experiments. a, b ***P= 0.0004, *P= 0.04,
**P= 0.0018, using two-tailed unpaired Student’s t test. d, f *P= 0.02, **P= 0.007, ****P < 0.0001, using two-tailed unpaired Student’s t test.
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required for cell survival and differentiation49. Though HIF1α is
primarily essential for T cell activation and differentiation of
effector T cells, emerging data indicates that HIF2α plays an
indispensable role in regulatory T cell functions59.
Our RNA-Seq analysis demonstrated an upregulation of HIF1α,
which is a critical transcription factor required for Th9 cell
differentiation23. The glycolytic and hypoxia pathways were also
found to be differentially expressed in Th9 cells. Corroborating with
the published study, our findings also showed that HIF1α binds and
transactivates Il9 promoter resulting in enhanced Th9 cell differ-
entiation. Physiologically, HIF1α inhibition repressed IL-9
induction in Th9 cells and subsequently promoted the tumor
development in B16-OVA melanoma tumor model. In addition, we
showed that HIF1α also binds to Il9 promoter in other IL-9-
producing Th cells such as Th2, Th17, and iTregs. IL-9 induction
was significantly abrogated in Th9, Th2, Th17, and iTregs when
HIF1α was knocked down suggesting that HIF1α globally regulates
IL-9 induction in all IL-9 producing Th cells.
Prolyl hydroxylases 2 (PHD2) is known to degrade and
destabilize HIF1α and so on knocking down Phd2 gene, stability
of HIF1α increases. We found that Phd2 knockdown in Th9 cells
resulted in increased expression of Il9, Hif1α and Th9-associated
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genes. Phd2 knockdown also led to higher IL-9 induction in Th2,
Th17, and iTregs. Consistent with our published human data, we
also found a higher expression of Hif1α, Il9, and other signature
genes in mouse Th9 cells under hypoxia as compared to nor-
moxia. Furthermore, there was also an enhanced induction of IL-
9 in Th2, Th17, and iTregs under hypoxia indicating that con-
stitutive expression of HIF1α in hypoxic condition promotes
enhanced IL-9 induction in all IL-9 producing Th cells.
Corroborating with the published literature, we found that there
was an impaired induction of IL-9 and Th9-associated genes in
Nos2−/− Th9 cells. We also showed that Nos2−/− abrogates IL-9
induction in Th2, Th17, and iTregs. Previously, we have shown that
HIF1α and NO synergistically promote human Th9 cell
differentiation38. Molecularly, we found that HIF1α binds and
transactivates Nos2 promoter in Th9 cells. Thus, there was a
reduced Nos2 expression in Hif1αkd Th9 cells. Likewise, there was
an increased expression of Nos2 in Th9 cells differentiated under
hypoxia or when Phd2 was knocked down, both of which mimic
constitutive expression of HIF1α in Th9 cells respectively. Fur-
thermore, we found that NO, in turn, regulates HIF1α expression in
Th9 cells since Nos2−/− Th9 cells showed downregulated Hif1α
expression. These data establish a functional interaction between
HIF1α and NO in which both positively regulates each other
potentiating Th9 cell differentiation synergistically. Moreover, we
also found that EGFR-HIF1α pathway cooperatively regulates IL-9
induction in human Th9 cells. There was a higher induction of IL-9
and EGFR in human Th9 cells. EGFR inhibition substantially
suppressed while Areg treatment significantly enhanced IL-9
induction in human Th9 cells.
HIF1α is a central metabolic regulator of T cell
differentiation49, and we and others have shown that HIF1α is
essential for glycolytic activity in both mouse and human Th9
cells23,38. Th9 cells are highly glycolytic as compared to other Th
cells, however, the role of other metabolic pathways in Th9 cell
differentiation remains unexplored. Thus, we sought to undertake
a detailed understanding of different metabolic pathways in Th9
cells which are primarily regulated by HIF1α. Our whole cell
metabolomics analysis of mouse Th9 cells from WT and Hif1αkd
mice identified decreased production of metabolites of TCA, PPP,
fatty acid pathways, and energy metabolites apart from glycolysis
in the absence of HIF1α. This reflects the importance of HIF1α as
a key regulator of metabolic pathways in Th9 cells.
In addition, TCA cycle metabolite, α-Ketoglutarate (αKG), was
also regulated by HIF1α in Th9 cells. It has been shown that αKG
negatively regulates HIF1α stability through increased activation
of Egln1, gene encoding for PHD250. Here we showed that αKG
increases the expression of Egln1, which decreases HIF1α activity
resulting in the inhibition of Th9 cells. Furthermore, vigabatrin,
which increases the accumulation of αKG, suppressed HIF1α and
IL-9 induction in Th9 cells suggesting that αKG negatively reg-
ulates Th9 cell differentiation. Further, it has been shown that
succinate promotes HIF1α stabilization by impairing PHD2
activity in macrophages50. Our data suggests a higher induction
of IL-9, HIF1α, and Th9-associated genes in Th9 cells in the
presence of succinate indicating that succinate positively regulates
Th9 cell differentiation possibly by repressing PHD2 and
enhancing HIF1α activity. Consequently, succinate treatment
enhanced the anti-tumor potency of Th9 cells.
In summary, we have demonstrated the role of EGFR-HIF1α
pathway in the differentiation of IL-9-producing Th cells. Th9
cells produce Areg, which activates EGFR resulting in the acti-
vation of the downstream HIF1α signaling pathway. NO and
hypoxia stabilizes HIF1α which, in turn, induces NO potentiating
Th9 cell differentiation. TCA cycle metabolite, Succinate pro-
motes HIF1α stability and subsequently IL-9 induction in Th9
cells. Areg produced by Th9 cells further amplifies Th9 cell dif-
ferentiation in a feed-forward loop. In conclusion, this study
deciphers the molecular pathway involved in the regulation of IL-
9 induction in Th cells and its subsequent implication in Th9 cell-
mediated anti-tumor immune response, which could be poten-
tially targeted for successful cancer immunotherapy.
Methods
Mice. C57BL/6 (#000664), OT-II TCR (#004194), and Nos2−/− (#002596) mice
were procured from Jackson laboratory, housed and maintained in a pathogen-free
small animal facility (SAF) at the Translational Health Science and Technology
Institute (THSTI), Faridabad, India. Mice were housed in individual ventilated cages
supplemented with acidified water. The temperature for mice rooms at THSTI-SAF
were maintained between ~19–26 °C with ~30–70% humidity. Mice were housed
with 14 h light/10 h dark cycles. All mice experiments were performed in laminar
floor hoods, and all personnel were required to wear personal protective equipment.
Egfrflox/floxXCd4-cre mice were provided by D.M.W. Zaiss. The experiments on
Egfrflox/floxXCd4-cre mice32 were performed at the University of Edinburgh in
accordance with university ethical guidelines and the samples were shipped on dry
ice to THSTI, India where subsequent assays were performed. Areg−/− mice were
provided by Fiona Powrie and Phd2kd and Hif1αkd mice were provided by Chris W.
Pugh respectively. The experiments on Areg−/−31, Phd2kd 47, and Hif1αkd 47 were
performed at Kennedy Institute of Rheumatology, University of Oxford, United
Kingdom in accordance to the institutional ethical guidelines and the samples were
shipped on dry ice to THSTI, India for performing further assays and analysis. All
the mice used for experiments were 6–12 weeks old and both age and sex matched.
All animal experiments were performed in accordance to the THSTI Animal Ethical
guidelines.
Transcriptome profiling using RNA sequencing. RNA extracted from the
in vitro differentiated T cells was subjected to next-generation sequencing (NGS) to
generate deep coverage RNA-Seq data. Sequencing libraries of Poly A selected
mRNA were generated from the double-stranded cDNA using the IlluminaTruSeq
kit according to the manufacturer’s protocol. Library quality control was checked
using the Agilent DNA High Sensitivity Chip and qPCR. High quality libraries
Fig. 6 NO and HIF1α synergistically triggers IL-9 induction in Th9 cells. a–c Naïve CD4+ T cells from WT and Nos2−/− mice were differentiated to Th9
cells followed by a qPCR analysis of Spi1, Irf4, Gata3 and Batf expression. Data are representative of mean ± SEM from three independent experiments.
b FACS staining for IL-9 and IL-17 in Th9 cells. c qPCR analysis of Hif1α expression. Data are representative of mean ± SEM from three independent
experiments. d Bioinformatics analysis of HIF1α binding motif in Nos2 promoter followed by ChIP analysis of HIF1α binding to Nos2 promoter in Th9 cells
represented as enrichment of HIF1α on Nos2 promoter relative to input. Data are representative of mean ± SEM from three independent experiments.
e Luciferase assay for Nos2 promoter activity in the presence of HIF1α plasmid at 0, 50, and 100 ng concentrations. Data are representative of mean ± SEM
from three independent experiments. f Naïve CD4+ T cells from WT and Hif1αkd mice were differentiated under Th9 polarizing conditions with daily
treatment of 1.0 μg/ml Dox for 3 days followed by qPCR analysis of Nos2 expression. Data are representative of mean ± SEM from three independent
experiments. g Naïve CD4+ T cells from WT mice were differentiated into Th9 cells under normoxic (21% oxygen) or hypoxic (1% oxygen) conditions for
3 days followed by qPCR analysis of Nos2 expression. Data are representative of mean ± SEM from three independent experiments. h Naïve CD4+ T cells
from WT and Phd2kd mice were differentiated under Th9 polarizing conditions with daily treatment of 1.0 μg/ml Dox for 3 days followed by qPCR analysis
of Nos2 expression. Data are representative of mean ± SEM from three independent experiments. a, c ****P < 0.00001, *P= 0.01, using two-tailed unpaired
Student’s t test. d **P= 0.0017, using two-tailed unpaired Student’s t test. e ****P < 0.00001, using one-way ANOVA followed by Tukey’s multiple
comparison test. f *P= 0.01, using two-tailed unpaired Student’s t test. g *P= 0.04, using two-tailed unpaired Student’s t test. h **P= 0.0026, using two-
tailed unpaired Student’s t test.
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were sequenced on an Illumina HiSeq 2500. To achieve comprehensive coverage
for each sample, ~25–30 million paired end reads were generated.
RNA-Seq data analysis. The Quality check of the sequenced read were performed
by FASTQC (version 0.11.9) and FASTX (version 0.0.13) to remove the adapter
and unwanted low quality reads. Tophat2 and Bowtie2 packages were used to align
the cleaned reads to the reference mouse genome (GRCm38). Subsequently, Htseq-
count algorithm were used to measure gene expression from aligned reads. The
read count-based gene expression data were normalized on the basis of library
complexity and gene variation using the R package Cuffdiff. The normalized count
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data were compared between groups to identify differentially expressed genes.
Genes were considered significantly differentially expressed if the P-value was
>0.0001 FDR and absolute fold change cut-off was >2.60,61. The downstream
analysis was done by in-house script (Supplementary data 1).
Ingenuity Pathway analysis. Ingenuity Pathway Analysis (IPA 8.0, Qiagen) was
used to identify the pathways that are significantly affected by differentially
expressed genes. The knowledge base of this software consists of functions, path-
ways, and network models derived by systematically exploring the peer reviewed
scientific literature. It calculates P-value for each pathway according to the fit of
user’s data to the IPA database using one-tailed Fisher exact test. The pathways
with multiple test corrected P-values <0.01 were considered significantly affected62.
NanoString analysis. The NanoString experiments were performed as per the
manufacture’s protocol. Briefly, ~80 ng of total RNA was isolated and hybridized
with reporter and capture probes in custom-made T helper cell-targeted nCounter
Gene Expression code set according to manufacturer’s instructions (NanoString
Technologies). Data were analyzed using nSolver Analysis software63.
Fig. 7 Succinate enhances HIF1α-mediated Th9 cell differentiation and anti-tumor immunity. a–e Naïve CD4+ T cells from WT and Hif1αkd mice were
differentiated under Th9 polarizing conditions. Samples were prepared and subjected to metabolomics. Heat-maps showing a global distribution and
quantification of metabolites in the cell extracts; b differentially expressed metabolites of glycolytic pathway; c differentially expressed currency
metabolites in cell extract; d footprinting quantification of differentially expressed metabolites in the cell culture supernatants, and e differentially
expressed metabolites of TCA cycle in the cell extracts. f Naïve CD4+ T cells from WT mice were differentiated to Th0 and Th9 with or without 1.0 mM
αKG, followed by NanoString analysis of mRNA expression in Th9 and Th9+ αKG conditions. Fold change in relative expression relative to control as
determined by log2 (Th9+ αKG/Th9 WT). g–i Naïve CD4+ T cells from WT mice were differentiated to Th0 and Th9 with or without 1.0 mM αKG
followed by g qPCR analysis of Hif1α and Il9 expression. Data are representative of mean ± SEM from three independent experiments. h FACS analysis of
intracellular IL-9 and IL-17 staining, and i mRNA expression of Egln1. Data are representative of mean ± SEM from three independent experiments. j–l Naïve
CD4+ T cells from WT mice were differentiated into Th9 cells with or without 5.0 mM succinate followed by j qPCR analysis of Il9, Spi1, Irf4, Irf1, and Gata3
expression. k FACS analysis of intracellular IL-9 and IL-17 production and ELISA for IL-9. l qPCR analysis of Hif1α and Egln1 mRNA expression. Data are
representative of mean ± SEM from three independent experiments. m Naïve CD4+ T cells from OT-II TCR transgenic mice were differentiated into Th9
cells with or without 5.0 mM succinate. At day 4, cells were adoptively transferred into B16-OVA tumor-bearing WT mice. Mean tumor volume was
measured over time. Data represent one of the three experiments with three independently analyzed mice/group (n= 3 mice per group). g *P= 0.009,
using one-way ANOVA followed by Tukey’s multiple comparison test. i **P= 0.004, using two-tailed unpaired Student’s t test. j **P= 0.0027, ***P=
0.0002, ****P < 0.0001, *P= 0.011, using two-tailed unpaired Student’s t test. k. P = ns (not significant), using one-way ANOVA followed by Tukey’s
multiple comparison test. l **P= 0.0046, ****P < 0.0001, ***P= 0.0001, using one-way ANOVA followed by Tukey’s multiple comparison test. m ****P <
0.0001, *P= 0.033, using two-way ANOVA followed by Tukey’s multiple comparison test.
Fig. 8 Schematic representation of EGFR-HIF1α signaling pathway in Th9 cells. TGF-β1 and IL-4 initiates the “differentiation” of naïve CD4+ T cells into
Th9 cells, which expresses EGFR and produces EGFR ligand, Areg. Areg “amplifies” Th9 cell differentiation via activating EGFR in a feed-forward loop. Upon
activation, EGFR triggers downstream “signaling” through HIF1α which transactivates Il9 and Nos2 promoters resulting in enhanced IL-9 induction.
Succinate, a TCA cycle metabolite, and nitric oxide (NO) further stabilizes HIF1α potentiating Th9 cell differentiation and anti-tumor effector functions.
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In vitro mouse T helper cells differentiation. 6–12 weeks old WT mice were
euthanized and spleen and lymph nodes were collected aseptically. Single cell
suspensions from spleen and lymph nodes were prepared after lysing red blood
cells using ACK lysis buffer. Cells were then stained with the cell surface anti-
bodies- anti-mouse CD4 PerCP (RM4-5; BioLegend Cat # 100538; 1:200), anti-
mouse CD62L APC (MEL-14; BioLegend Cat # 104412, 1:200), and anti-mouse
CD25 PE (3C7, BioLegend Cat # 101904, 1:200). Cells were sorted on BD FACS
Aria III with approximately >98% purity.
Sorted purified naïve (CD4+CD62L+) T cells were activated with plate bound
anti-CD3 (2.0 μg/ml; 145-2C11; Bio X Cell; Cat # BE0001-1) and anti-CD28
(2.0 μg/ml; 37.51; Bio X Cell; Cat # BE0015-1), and were in vitro differentiated
using the following cytokines: Th1 [IL-12 (10 ng/ml)], Th2 [IL-4 (10 ng/ml)], Th9
[TGF-β1 (2.0 ng/ml), IL-4 (20 ng/ml)], Th17 [TGF-β1 (2.0 ng/ml), IL-6 (25 ng/
ml)], and iTregs [TGF-β1 (2.0 ng/ml), IL-2 (50 U/ml)] for 3 days respectively. In
addition, Areg (100 ng/ml), IL-33 (10 ng/ml) and TSLP (10 ng/ml) were added
during differentiation, wherever indicated. Hypoxia experiments were carried out
in a hypoxia chamber (Coy Laboratory Products) inside which cells were
differentiated at 1.0% oxygen for 3 days.
In vitro human T helper cells differentiation. 10 ml of peripheral blood was
collected from healthy human volunteers after written informed consent in
accordance with the approval of the institutional human ethics committee. Per-
ipheral blood mononuclear cells (PBMCs) were isolated from whole blood using
ficoll-paque based density gradient centrifugation and were then stained with the
following cell surface fluorochrome-labelled antibodies: anti-human CD4 Horizon
V450 (RPA-T4; BD Biosciences Cat # 560345; 1:200), anti-human CD45RA PE/
Cy7 (HI100; BioLegend Cat # 304126; 1:200) and anti-human CD45RO APC
(UCHL1; BioLegend Cat # 304210; 1:200) and subjected to sorting on BD FACS
Aria. Naïve CD4+ T cells (CD4+CD45RA+CD45RO‒) were sorted on BD FACS
Aria III with >95% purity.
Naïve CD4+ T cells (CD4+CD45RA+CD45RO−) were activated with plate
bound anti-hCD3 (10 μg/ml; OKT-3; Bio X Cell Cat # BE0001-2) and soluble anti-
hCD28 (2.0 ug/ml; CD28.2; BD Biosciences Cat # 555725) for 6 days in the
presence of TGF-β1 (2.0 ng/ml) and IL-4 (20 ng/ml) for Th9 differentiation.
100 ng/ml recombinant Areg was added during Th9 cell differentiation wherever
indicated.
qPCR. Differentiated T cells were lysed in RLT buffer (Qiagen), RNA was extracted
using the RNAeasy Mini Kit (Qiagen; #74104) and reverse transcribed into cDNA
using the iScript cDNA synthesis kit (Biorad; #1708891). qPCR was done using
KAPA SYBR® FAST qPCR Master Mix (2X) Universal Kit (KK4600) on Fast 7500
Dx Real-Time PCR system (Applied Biosystems). Results were analyzed with
SDS2.1 software. The cycling threshold value of the endogenous control genes, β-
actin (for mouse) and Gapdh (for human) was subtracted from the cycling
threshold value of each target gene to generate the change in cycling threshold
(ΔCT). The relative expression of each target gene is expressed as “fold change”
relative to that of unstimulated samples (2-ΔCT). We used the previously used
formula (POWER(2,−ΔCT)*10,000 to calculate the relative gene expression64. The
SYBR primers used for the analysis are mentioned in Supplementary Table 1.
Cytokine ELISA. Cytokines were measured in the culture supernatants by sand-
wich enzyme-linked immunosorbent assay (ELISA) as described64. Plates were read
at 405 nM and the absolute quantity of cytokines were determined using standard
for the respective cytokines. ELISA for mouse Areg was performed using kit from
Cloud-Clone (SEA006Mu).
Intracellular cytokine staining and Flow cytometry. In vitro differentiated T cells
were re-stimulated with PMA (phorbol 12-myristate13-acetate; 50 ng/ml; Sigma-
Aldrich), ionomycin (1.0 μg/ml; Sigma-Aldrich), and monensin (GolgiStop, BD
Biosciences Cat # 554724) for 6 h64. Cell surface staining was done for 15–20 min
with anti-mouse CD4 [RM4-5; BioLegend (CD4 PerCP Cat # 100538, CD4 PE Cat
#100512, CD4 APC Cat # 100516); 1:200] and anti-mouse CD8a PerCP (53-6.7;
BioLegend Cat # 100732; 1:200) for mouse; and anti-human CD4 APC (OKT4,
BioLegend Cat # 317416; 1:200) for human after live/dead marker staining
respectively. For intracellular staining, cells were fixed in Cytofix solution and
permeabilized with 1X Perm/Wash Buffer using kit (BD Biosciences Cat # 554714).
Cells were then stained with anti-mouse IL-17A [TC11-18H10.1; BioLegend (IL-
17A APC Cat # 506916, IL-17A PE/Cy7 Cat # 506922, IL-17A PerCP/Cy5.5 Cat
# 506920, IL-17A Pacific Blue Cat # 506918, IL-17A FITC Cat # 506908; 1:200],
anti-mouse IL-9 [RM9A4; BioLegend (IL-9 PE Cat # 514104, IL-9 PerCP/Cy5.5
Cat # 514112, IL-9 APC Cat # 514106) 1:200], anti-mouse IFN-γ PE/Cy7 (XMG1.2;
BioLegend Cat # 505826; 1:200) or anti-human IL-9 [MH9A4; BioLegend (IL-9
PerCP/Cy5.5 Cat # 507610, IL-9 PE Cat # 507605) 1:200] in Perm/Wash buffer.
The cells were acquired using flow cytometry on FACSCantoII with FACSDiva
software version 8.0.2 (BD biosciences) or on FACSVerse (BD Biosciences) and the
results were analyzed with FlowJo software version 10 (Tree Star).
Luciferase reporter assay. HEK293T cells were transiently transfected with HA-
HIF1α-pcDNA3 (Addgene; # 18949) and the respective promoters construct,
pGL3-IL-9 promoter luciferase or pGL2-Nos2 promoter luciferase (Addgene;
# 19296) tagged with firefly luciferase reporter, and renilla luciferase reporter vector
using X-treme GENETM 9 DNA Transfection Reagent (# 06365787001; Roche).
For pGL3-IL-9 promoter luciferase plasmid construct, the mouse Il9 promoter
region (NC_000079.6) from +7177 to +9277 was amplified from genomic DNA by
PCR with the forward primer (5′-ATGCACGCGTTCTGTCAGAGA-
GAGGTGTAG-3′) and the reverse primer (5′-ATG CCCCGGGTCAGTCTAC-
CAGCATCTTCC-3′). The amplified fragment was cloned into the pGL3 basic
luciferase reporter gene vector (Promega) at MluI and SmaI restriction sites.
Luciferase luminescence was measured after 48 h of transfection by using Dual Glo
Luciferase Reporter Assay system as per manufacturer’s protocol (Promega;
E2940). Firefly luciferase activity was normalized to renilla luciferase activity and
the result was represented as relative light units (RLU).
Chromatin immunoprecipitation (ChIP). 1 × 107 naïve mouse CD4+ T cells were
differentiated in vitro into Th2, Th9, Th17, and iTregs for 3 days followed by cross-
linking with 1% formaldehyde to preserve the DNA-protein interactions. Samples
were further processed for enzymatic digestion of chromatin using SimpleChIP®
Enzymatic Chromatin IP Kit (Cell signaling technology; Cat # 9003S). Lysates were
sonicated and immunoprecipitated with anti-HIF1α antibody (Abcam; Cat
# ab228649; 5.0 μg per immunoprecipitation) or Rabbit IgG Isotype Control (ChIP
grade) antibody (Abcam; Cat # ab171870; 1.0 μg per immunoprecipitation)
respectively. DNA was eluted after reverse cross-linking of immunoprecipitated
complex followed by qPCR. The putative binding sites of HIF1α on IL-9P and
Nos2P promoters were amplified respectively by quantitative qPCR (SYBR Green
chemistry). The values were subtracted from the amount of isotype IgG negative
control and were normalized to the corresponding input control. The results were
expressed as percent of total input control. List of the primers used for amplifi-
cation are mentioned in Supplementary Table 2.
Mass spectrometry-based metabolomics analysis using ion chromatography.
Naïve CD4+ T cells from WT and Hif1αkd mice were differentiated in vitro into
Th9 cells for 3 days. 1 × 106 cells were incubated in RPMI (glucose-free formula-
tion) containing 10 mM [U-13C] glucose (Cambridge Isotope Laboratories), 2.0
mM glutamine, and 10% dialyzed FBS at 37 °C for 1 h. Cells were washed in 150
mM of ice-cold ammonium acetate (pH 7.3) and metabolites were extracted in 80%
methanol on dry ice followed by evaporation under vacuum. Dried metabolites
were resuspended in 50% acrylonitrile (ACN) and 1/10th was loaded onto a Luna
3 μm NH2 100 A (150 × 2.0 mm) column (Phenomenex). The chromatographic
separation was performed using an UltiMate 3000 RSLC (Thermo Scientific) with
mobile phases A (5 mM NH4AcO pH 9.9) and B (ACN) and a flow rate of 200 μl/
min. The gradient from 15% A to 95% A over 18 min was followed by 9 min
isocratic flow at 95% A and re-equilibration to 15% A. Metabolite detection was
achieved with a Thermo Scientific Q Exactive mass spectrometer run with polarity
switching in Full Scan mode with an m/z range of 65–975. TraceFinder 4.1
(Thermo Scientific) was used to quantify metabolites by area under the curve using
retention time and accurate mass measurements (<3 ppm). Moreover, cell-free
culture supernatants were also collected and subjected to mass spectrometry-based
metabolomics analysis using ion chromatography for the quantification of secreted
metabolites (metabolic footprinting). Data analysis was performed using in-house
scripts in the statistical language R. Statistical differences were determined by one-
way ANOVA testing.
Adoptive transfer and B16-OVA melanoma tumor model. B16F10 melanoma
cell line expressing ovalbumin (B16-OVA) was grown in RPMI 1640 supplemented
with 10% FBS and 100 U/ml Pen/Strep. 2 × 105 B16-OVA cells were sub-
cutaneously injected into the right flank region of 6–8-week-old female WT mice
for the development of melanoma. To investigate the in vivo role of EGFR, HIF1α
and succinate in Th9 cell-mediated anti-tumor immune response, naïve CD4+
T cells from OT-II TCR transgenic mice (which specifically recognize OVA) were
differentiated into Th9 cells with or without gefitinib, acriflavine, and succinate
respectively, added at the indicated concentrations. 2 × 106 OVA-specific Th9 cells
(±gefitinib, acriflavine, succinate) were intravenously injected into the B16-OVA
tumor-bearing mice respectively at day 5 after the appearance of small
palpable tumor.
Tumor growth was monitored and tumor volume was measured every 2 days
using vernier caliper. Tumor volume was calculated as: volume (mm3)= L ×W2 /2,
where L is the length and W is the width of the tumor (in mm). Mice were
euthanized when the tumor volume exceeded 2000 mm3 or there was severe skin
necrosis defined as the end point of the study22,28. Spleen (Spl) and tumor draining
lymph nodes (dLN) were aseptically removed from all the mice at the end point
and were further processed to make single cell suspension. Cells were re-stimulated
ex vivo with PMA and ionomycin for intracellular cytokine staining for analyzing
the expression of CD4+ and CD8+ T cells producing IFN-γ using flow cytometry
as described22,28.
Isolation of tumor-infiltrating lymphocytes (TILs). In adoptive transfer B16-
OVA melanoma tumor model experiment, mice were euthanized and tumors were
excised, enzymatically digested with collagenase D (Roche; 11088858001) followed
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by mechanical disruption using gentleMACSTM Dissociator (Miltenyi Biotec)28.
The cells were washed with media and passed through 40 µm strainer and sub-
jected to percoll density gradient centrifugation yielding separate layers out of
which a faint layer near to 63% percoll gradient in the tube was collected and
washed twice with 1x PBS. The resulting cell pellet consists of TILs28. TILs were
further re-stimulated ex vivo with PMA/ionomycin for six hours and stained with
respective fluorochrome-tagged FACS antibodies for intracellular cytokine staining
for analyzing the expression of CD4+ and CD8+ T cells producing IFN-γ using
flow cytometry as described28.
Statistical analysis. GraphPad Prism 7.0 software was used for statistical analysis.
Unpaired two-tailed Student’s t test for comparison of means between two groups;
one-way ANOVA for comparison of means between more than two groups and
two-way ANOVA test for comparison among multiple groups with two variables
were used. All the statistical tests were followed by Tukey’s multiple comparison’s
post-test. Differences were considered statistically significant with a P-value < 0.05
for all the experiments. All the data depicted in the bar graphs and scatter dot plots
are represented as mean ± SEM.
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
Data availability
Sequence data that support the findings of this study have been deposited in GEO with
the primary accession code, GSE163056. Publicly available data with accession code,
GSE100634, were reanalyzed. The authors declare that all other data supporting the
findings of this study are available within the article and its supplementary
information files.
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